Loss widens year-over-year. Harvard Bioscience Inc (NASDAQ: HBIO) reported a loss of $0.06 per share for Q4 2025, matching the prior quarter’s loss of $0.06 but swinging from a profit of $0.06 per share in Q4 2024. The medical instruments supplier posted a net loss of $2.8 million for the quarter.
Revenue slips 3.3% year-over-year. Q4 2025 revenue came in at $23.7 million, down 3.3% from $24.6 million in the year-ago quarter. Revenue held flat sequentially at $23.7 million versus Q3 2025. The company generated gross profit of $14.2 million and operating income of $1.7 million, with adjusted EBITDA of $3.8 million. Management issued Q1 2026 revenue guidance of $22.5 million to $24.5 million, suggesting the midpoint of $23.5 million would represent another modest sequential decline.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.